Daré Bioscience Achieves Second Positive Ovaprene DSMB Review, Eyes June Product Revenue
Daré Bioscience secured a second consecutive positive DSMB review of interim Phase 3 Ovaprene data, advancing its hormone-free monthly contraceptive toward potential FDA approval. The company expects first product revenue in June 2026, with DARE to PLAY dispensing starting in Q3 and Flora Sync LF5 launching summer 2026.
1. Ovaprene Phase 3 Advancement
Daré secured a second consecutive positive DSMB review on interim data from its Phase 3 Ovaprene trial, reinforcing safety and efficacy signals for the first hormone-free monthly contraceptive candidate eligible for FDA approval. The trial now proceeds with confidence toward potential filing.
2. DARE to PLAY Dispensing Plans
DARE to PLAY topical sildenafil cream, clinically shown to boost genital blood flow within 10–15 minutes, has been available for pre-fulfillment prescribing nationwide since February. Full national dispensing via Bravado Pharmaceuticals is targeted to begin in Q3 2026 as state licensing and fulfillment preparations complete.
3. Flora Sync LF5 Commercial Launch
Flora Sync LF5, a vaginal probiotic suppository supporting microbiome balance, is slated for commercial launch in summer 2026, marking Daré’s first direct product revenue expected to begin in June. Distribution will leverage the DARE Health Hub telehealth infrastructure.
4. Commercial and Financial Outlook
The company anticipates monthly product revenue as early as June 2026, supported by an asset-light 503B compounding strategy and telehealth-driven distribution. Equity financing and non-dilutive grant funding underpin continued R&D and advancement of a 505(b)(2) NDA pathway for DARE to PLAY.